BRAF inhibitors are highly effective against melanoma, non-small cell lung cancer, differentiated thyroid tumor, colorectal cancer, cholangiocarcinoma, and other tumors with the BRAF V600E mutation28. This evidence concerns the gene BRAF and non-small cell lung carcinoma.